Skip to main content
. Author manuscript; available in PMC: 2020 Aug 31.
Published in final edited form as: Epigenomics. 2012 Oct;4(5):571–589. doi: 10.2217/epi.12.52

Figure 3. The romidepsin–bortezomib regimen overcomes drug-resistance in human myeloma cells.

Figure 3.

(A) Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human myeloma cells were exposed (24 h) to 1 nM FK228 ± 2 nM Btzmb, after which the percentage of Annexin V+ (apoptotic) cells were determined by flow cytometry. (B) Btzmb-resistant cells (U266/PS-R) were generated by culturing U266 cells in gradually increasing concentrations of Btzmb up to 12 nM. U266/PS-R cells were treated for 48 h with 2 nM FK228 in the absence or presence of 5–15 nM Btzmb, after which apoptosis was assessed by Annexin V-FITC staining and flow cytometry.

Btzmb: Bortezomib; Ctrl: Control; FK228: Romidepsin.

[Grant S, Dai Y, Unpublished data].